The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

Frontiers in Endocrinology

Endocrinology

Li Yang¹  Jun Huang²  Hua Zhang²  Zhi Li²  Bei Wang²  Qun Wang²  Geng Wang²  Jie Yuan³  Gautam Sethi⁴  Chakrabhavi Dhananjaya Mohan⁵ 

[1] Department of Clinical Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Hubei, China;Department of Endocrine and Vascular Surgery, Taihe Hospital, Hubei University of Medicine, Hubei, China;Department of Endocrine and Vascular Surgery, Taihe Hospital, Hubei University of Medicine, Hubei, China;Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore;Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore;Department of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysore Karnataka, India;FEST Division, CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India;

关键词: breast cancer;    endocrine therapy resistance;    estrogen;    tumor microenvironment;    drug resisitance;   

DOI  :  10.3389/fendo.2023.1261283

 received in 2023-07-19, accepted in 2023-09-29,  发布年份 2023

来源: Frontiers

【 摘 要 】

Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients. Resistance to endocrine therapy demands the design of newer therapeutic strategies. The understanding of underlying molecular mechanisms of endocrine resistance, components of the tumor microenvironment (TME), and interaction of resistant breast cancer cells with the cellular/acellular components of the intratumoral environment are essential to formulate new therapeutic strategies for the treatment of endocrine therapy-resistant breast cancers. In the first half of the article, we have discussed the general mechanisms (including mutations in estrogen receptor gene, reregulated activation of signaling pathways, epigenetic changes, and cell cycle alteration) responsible for endocrine therapy resistance in hormone-positive breast cancers. In the latter half, we have emphasized the precise role of cellular (cancer-associated fibroblasts, immune cells, and cancer stem cells) and acellular components (collagen, fibronectin, and laminin) of TME in the development of endocrine resistance in hormone-positive breast cancers. In sum, the article provides an overview of the relationship between endocrine resistance and TME in hormone-positive breast cancers.

【 授权许可】

Unknown   
Copyright © 2023 Yuan, Yang, Li, Zhang, Wang, Huang, Wang, Mohan, Sethi and Wang